This is a luncheon presentation with Arthur Tinkelenberg, CEO of Enumeral (OTCQB: ENUM).  Located in Cambridge, MA, Enumeral is a biopharmaceutical company focused on discovering and developing antibodies for the treatment of cancer and inflammatory diseases.

Company highlights include:

•          Enumeral uses cells from the human immune system and a platform developed at MIT, Harvard, Whitehead Institute and MGH to discover rare antibodies that may have the characteristics essential to become a safe and effective drug
•          The Company is focusing initially on the hot topic of cancer immunotherapy, where many major partnerships and financing deals have taken place over the last year and a large unmet medical need exists
•          Enumeral has conducted proof-of-concept studies in collaboration with leading biotech/pharma companies and plans to enter two additional collaborations by mid-2015
• PPO and reverse merger in August 2014

The format of this non-deal roadshow meeting is 15 minutes of networking, a 30-minute presentation over lunch, concluding with 15 minutes of Q&A.